1st Edition
Abdominal Obesity and the Endocannabinoid System From Basic Aspects to Clinical Management of Related Cardiometabolic Risk
This internationally renowned author team provides a unique and thorough analysis and distillation of the endocannabinoid system and its relationship to abdominal obesity, diabetes, and cardiovascular disease. The endocannabinoid system (ECS) plays an important role in cardiometabolic risk, as well as modulating energy balance, feeding behavior, hepatic lipogenesis, and perhaps glucose homeostasis. Evidence suggests that the ECS is overactive in human obesity and dyslipidemia.
Critical to the management of cardiometabolic risk, this new, timely book provides practical overviews and management guidance on many important topics, including:
- abdominal obesity and the metabolic syndrome
- the endocannabinoid system and energy balance: functions and dysfunctions
- abdominal obesity, the EC system, and cardiometabolic risk
Abdominal Obesity, Metabolic Syndrome, and Risk of Cardiovascular Disease
Jean-Pierre Despr´es and Vincenzo Di Marzo
Abdominal Obesity in Type Diabetes
Isabelle Lemieux and Jean-Pierre Despr´es
Obesity and Hypertension
Paul Poirier and Caroline Rh´eaume
Visceral Adiposity, Liver Fat, and Atherogenic Dyslipidemia
Marja-Riitta Taskinen, Martin Adiels, and Jan Bor´en
Visceral Adiposity and Inflammation
Ulf Smith
Abdominal Obesity and Alterations in Haemostasis—Thrombosis
Ir`ene Juhan-Vague and Marie-Christine Alessi
Physiological and Metabolic Characteristics of Visceral Adipocytes
Alain Veilleux and Andr´e Tchernof
The Endocrine Function of Adipose Tissue: Implications of Visceral Obesity for Patients
With Cardiometabolic Risk
Max Lafontan
Free Fatty Acid Metabolism in Visceral Obesity
Asem Ali and Michael D Jensen
Animal Models of Visceral Obesity
Derek M Huffman and Nir Barzilai
Insulin Sensitivity and Visceral Adiposity: Effects of Rimonabant
Joyce M Richey, Morvarid Kabir, Orison O Woolcott, Stella P Kim, Lisa N Harrison,
Darko Stefanovski, Isabel Hsu, Dan Zheng, Maya Lottati, Cathryn Kolka, Viorica Ionut, Karyn
Catalano, Jenny D Chiu, and Richard N Bergman
Physical Activity in the Management of Visceral Obesity and Related
Cardiometabolic Risk
Peter M Janiszewski and Robert Ross
Can We Change the Lifestyle of High-Risk Patients? Lessons from the Prevention
of Diabetes Trials
Jaakko Tuomilehto and Jaana Lindstr¨om
Can We Change the Body Fat Distribution Phenotype? Lessons from PPAR Agonists
Zubin Punthakee and Hertzel C Gerstein
Is There an Optimal Diet for the Management of Abdominal Obesity and Related
Cardiometabolic Risk
Benoˆıt Lamarche and Caroline Richard
The EC System and Central Control of Energy Balance—The Hypothalamus
Vincenzo Di Marzo
The EC System and Central Control of Energy Balance: The Nucleus Accumbens
Tim C Kirkham
The EC System and the HPA Axis
Daniela Cota
The EC System and Gut–Brain Interactions Relevant to Satiety
Richard Jones, Galina Burdyga, David G Thompson, and Graham J Dockray
The Endogenous Cannabinoid System in the Gastrointestinal Tract
Angelo A Izzo
The EC System in the Adipose Tissue and Endocrine Pancreas
Isabel Matias
The EC System in the Immune System and the Inflammatory Response
Tracy A Sherwood and Thomas W Klein
The Endocannabinoid System in the Liver
Ariane Mallat and Sophie Lotersztajn
The Endocannabinoid System and Cardiovascular Disease
P´al Pacher and George Kunos
The Endocannabinoid System, Energy Expenditure, and Thermogenesis
Luigi Bellocchio, Cristina Cervino, Valentina Vicennati, Renato Pasquali, and Uberto Pagotto
Effects of Dietary Fatty Acids on Endocannabinoid Signaling in the Brain and
Peripheral Organs
Alvin Berger and Vincenzo Di Marzo
Endocannabinoid Overactivity and Abdominal Obesity
Vincenzo Di Marzo and Jean-Pierre Despr´es
CB Antagonism in the Management of Abdominal Obesity
Luc F Van Gaal
Abdominal Obesity and the Endocannabinoid System CB Blockade, Insulin Resistance,
and Type Diabetes
Andr´e J Scheen
Abdominal Obesity As a Therapeutic Target to Manage the Atherogenic Dyslipidemia and
Related Metabolic Abnormalities
Jean-Pierre Despr´es
CB Blockade and Hypertension
Luis M Ruilope
Future Developments : CB Blockade forWeight Gain Subsequent
to Smoking Cessation
Jaimee L Heffner and Robert M Anthenelli
Future Developments : Cannabinoid CB Receptor Blockade in Weight Gain Subsequent
to Psychiatric Disorder Treatment
Ester Fride, Shimon Rabichev, and Nikolai Gobshtis
Index
Abdominal Obesity, Metabolic Syndrome, and Risk of Cardiovascular Disease. Abdominal Obesity in Type Diabetes. Obesity and Hypertension. Visceral Adiposity and Inflammation. Abdominal Obesity and Alterations in Haemostasis—Thrombosis. Physiological and Metabolic Characteristics of Visceral Adipocytes. The Endocrine Function of Adipose Tissue: Implications of Visceral Obesity for Patients. With Cardiometabolic Risk. Free Fatty Acid Metabolism in Visceral Obesity. Animal Models of Visceral Obesity. Insulin Sensitivity and Visceral Adiposity: Effects of Rimonabant. Physical Activity in the Management of Visceral Obesity and Related. Cardiometabolic Risk. Can We Change the Lifestyle of High-Risk Patients? Lessons from the Prevention of Diabetes Trials. Can We Change the Body Fat Distribution Phenotype? Lessons from PPAR Agonists. Is There an Optimal Diet for the Management of Abdominal Obesity and Related. Cardiometabolic Risk. The EC System and Central Control of Energy Balance—the Hypothalamus. The EC System and Central Control of Energy Balance: The Nucleus Accumbens. The EC System and the HPA Axis. The EC System and Gut–Brain Interactions Relevant to Satiety. The Endogenous Cannabinoid System in the Gastrointestinal Tract. The EC System in the Adipose Tissue and Endocrine Pancreas. The EC System in the Immune System and the Inflammatory Response. The Endocannabinoid System in the Liver. The Endocannabinoid System and Cardiovascular Disease. The Endocannabinoid System, Energy Expenditure, and Thermogenesis. Luigi Bellocchio, Cristina Cervino, Valentina Vicennati, Renato Pasquali, and Uberto Pagotto. Effects of Dietary Fatty Acids on Endocannabinoid Signaling in the Brain and. Peripheral Organs. Endocannabinoid Overactivity and Abdominal Obesity. CB Antagonism in the Management of Abdominal Obesity. Abdominal Obesity and the Endocannabinoid System CB Blockade, Insulin Resistance, and Type Diabetes Abdominal Obesity As a Therapeutic Target to Manage the Atherogenic Dyslipidemia and. Related Metabolic Abnormalities. CB Blockade and Hypertension. Future Developments: CB Blockade forWeight Gain Subsequent. To Smoking Cessation. Future Developments: Cannabinoid CB Receptor Blockade in Weight Gain Subsequent. To Psychiatric Disorder Treatment. Index.
Biography
JEAN-PIERRE DESPRÉS is Professor at the Division of Kinesiology of the Department of Social and Preventive Medicine at Université Laval, Québec, Canada. He received his Ph.D. in Exercise Physiology from Université Laval and then pursued a post-doctoral training at the Department of Medicine of the University of Toronto. Dr. Després is Director of Research at the Québec Heart Institute in Québec City and holds the position of Scientific Director of the International Chair on Cardiometabolic Risk, a multi-disciplinary academic organisation based at Université Laval. Dr. Després has been the Editor for the International Journal of Obesity from 1992 to 2000, and he is currently a member of the editorial boards of several scientific journals He also serves on the board of numerous organisation and has been the recipient of many awards. Dr. Després has published more than 480 papers in peer-reviewed journals and has written 50 book chapters.
VINCENZO DI MARZO is Research Director at the Istituto di Chimica Biomolecolare, Pozzuoli (Naples), Italy, and Adjunct Associate Professor at Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia, USA. Dr. Di Marzo received his first degree in chemistry from the University of Naples "Federico II", in Italy, and his Ph.D. in biochemistry from the Imperial College of Science. Technology & Medicine, London, UK. Among his many achievements, Dr. Di Marzo was the principal investigator of a Human Frontier in Science Organization grant and past president of the International Cannabinoid Research Society, and founded the Endocannabinoid Research Group, in which several laboratories working on endocannabinoids in the Naples area converge. He has coauthored over 340 articles in peer-reviewed scientific journals. In 2007 he received the Mechoulam Award for "his outstanding contributions to cannabinoid research".
